DESTINY-Breast04 Study Discussion with Dr. Shanu Modi

Share on facebook
Share on whatsapp
Share on twitter
Share on linkedin

Discussing the DESTINY-Breast04 study which resulted in a paradigm shift, with the introduction of low HER2 positive breast cancer, and further approval of Trastuzumab Deruxtecan (T-DXd). In discussion with the lead author, Dr. Shanu Modi – Professor of Medicine at Memorial Sloan Kettering Cancer Center. 

Subscribe Now

Document

Dr. Rahul

Dr. Rahul is a Chief of Medical Oncology, making up one-half of the ‘Oncology Brothers.’ He is a valued member of the Guthrie Corning Cancer Center, contributing his extensive knowledge of technology